|
Need for intervention
|
-Severity of the disease / condition
|
Target disease
|
|
- Population size
|
- Severity of the disease
|
|
-Unmet need / availability of alternatives
|
-Determinants of the disease
|
|
-Burden of illness / threat to life
|
|
-Economic burden of the disease
|
|
-Epidemiology
|
|
Therapeutic context
|
|
-Therapeutic alternatives / need not met
|
|
-Need
|
|
-Clinical practice guidelines and protocols
|
|
-Existing use
|
|
Health results
|
-Benefits in health / clinical
|
Clinical benefits
|
|
-Efficacy / Effectiveness
|
- General clinical benefits
|
|
- Safety / tolerability
|
-Effect on mortality
|
|
-Health perceived by the patient
|
-Effect on longevity
|
|
-Quality of care
|
-Effect on quality of life
|
|
Health perceived by the patient:
|
|
-Quality of life
|
|
- Autonomy
|
|
- Impact on dignity
|
|
- Improved use / administration
|
|
Adequacy
|
|
- Efficiency and safety
|
|
- Effectiveness
|
|
Response level
|
|
- Quality of care received by the patient
|
|
- Burden of disease
|
|
Type of benefit of the intervention
|
-Preventive benefits
| |
|
-Therapeutic benefits
|
|
Economic consequences / economic impact
|
-Costs of the intervention
|
Efficiency
|
|
- Medical / health costs
|
- Cost effectiveness / benefit
|
|
- Non-medical costs (productivity, cost, patients, caregivers)
|
- Budget impact
|
|
-Impoverishment for the patient
|
- Costs
|
|
- Budget impact
|
Financing
|
|
-Financial impact
|
- Unit cost
|
|
-Impact on productivity
|
- Budget impact
|
|
-Impact on other services
|
- Financing agent
|
|
-Efficiency and opportunity cost
|
Cost of opportunity and affordability (context-dependent criteria)
|
|
-Cost-effectiveness
|
- Opportunity cost and if the system can afford it
|
|
Existing knowledge about the intervention / Quality and uncertainty of the evidence
|
-Evidence available
|
Other considerations
|
|
-Quality of the evidence
|
Quality of clinical and economic evidence
|
|
-Relevance of the evidence
|
Consistency with strategic aspects
|
|
-Uncertainty of the evidence
|
|
-Expert consensus / clinical practice guidelines
|
|
Implementation and complexity of the intervention / Feasibility
|
-Regulatory requirements / legislation
|
|
-Organizational requirements
|
|
-Technological requirements
|
|
-Requirements of personnel
|
|
-Training / personal skills requirements
|
|
-Information requirements
|
|
-Implementation flexibility
|
|
-Features of the intervention
|
|
-Appropriate use
|
|
-Barriers and acceptability
|
|
-Integration and efficiency of the system
|
|
-Sustainability
|
|
-Accessibility to the population
|
|
Ethics and justice
|
-Population priorities
|
Priority, ethics and justice
|
|
-Access
|
- Low socioeconomic status
|
|
-Vulnerability
|
- Children (0–5 years old or elderly)
|
|
-Utility
|
- Subjects of productive age
|
|
-Solidarity
|
- Women in productive age
|
|
-Ethics and moral aspects
|
- Remote communities
|
|
- Therapeutic specific areas
|
|
- Response behavior
|
|
- Rare diseases
|
|
- Specific groups of patients
|
|
Equity
|
|
- General
|
|
- Accessibility
|
|
- Accessibility for the individual
|
|
Other ethical and social values
|
|
- Autonomy
|
|
- Value public health
|
|
- Impact in future generations
|
|
- Risk social and financial
|
|
- Catastrophic sanitary cost
|
|
- Economic productivity and care for third parties
|
|
- Rare diseases-Population priorities
|
|
Global context
|
-Mandate and mission of the health system
|
Governance / leadership
|
|
-Alignment with regulations and strategies
|
- Congruence with prior prioritization
|
|
- Global priorities / alignment with priority lines (vulnerable groups, disabled, diseases, rare, etc.)
|
- Cultural acceptability
|
|
-Financial Restriction
|
- Political acceptability
|
|
-Incentives
|
- Acceptability of interest groups
|
|
-Political aspects
|
- Legal Barriers
|
|
- Historical aspects
|
|
-Cultural aspects
|
|
-Degree of innovation
|
|
-Collaboration and leadership
|
|
-Implementation of patients
|
|
-Pressure of different interest groups
|
|
-Environmental impact
|
